-transparent.png){kind=logo}
OBJECTIVE To examine the association between the sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer. METHODS Meta-analysis of case-control studies using a random effects model. The "Main outcome measure" was the odds ratio for the risk of lung cancer, using extensive metabolisers as the reference group. RESULTS Thirteen studies were identified. The studies were too heterogeneous to be pooled the size of the odds ratio increased with the sample size. When the analysis was restricted to the largest studies, there was no difference in risk between poor and extensive metabolisers (odds ratio 0.95, 95% confidence interval 0.68-1.33). CONCLUSIONS No association was found between the CYP2D6 oxidation polymorphism and lung cancer risk when sample size bias was taken into account.
P M Christensen, and
P C Gøtzsche, and
K Brøsen
October 1990,
Pharmacology & toxicology,
P M Christensen, and
P C Gøtzsche, and
K Brøsen
January 1989,
European journal of clinical pharmacology,
P M Christensen, and
P C Gøtzsche, and
K Brøsen
June 1994,
Pharmacogenetics,
P M Christensen, and
P C Gøtzsche, and
K Brøsen
January 1986,
Progress in clinical and biological research,
P M Christensen, and
P C Gøtzsche, and
K Brøsen
January 1986,
Progress in clinical and biological research,
P M Christensen, and
P C Gøtzsche, and
K Brøsen
February 1994,
The Journal of pharmacology and experimental therapeutics,
P M Christensen, and
P C Gøtzsche, and
K Brøsen
January 1993,
European journal of clinical pharmacology,
P M Christensen, and
P C Gøtzsche, and
K Brøsen
January 1995,
Pharmacogenetics,
P M Christensen, and
P C Gøtzsche, and
K Brøsen
May 1991,
British journal of clinical pharmacology,
P M Christensen, and
P C Gøtzsche, and
K Brøsen
March 1998,
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology,
